From: Brian D Williams (talon57@well.com)
Date: Tue May 01 2001 - 08:46:10 MDT
http://www0.mercurycenter.com/front/docs1/ellison0429.htm
Posted at 10:58 p.m. PDT Saturday, April 28, 2001
Oracle's Ellison seeking Fountain of Youth
He spends millions on anti-aging quest
BY MATT MARSHALL
Mercury News
Centuries after America's early explorers searched in vain for the
fabled waters of the Fountain of Youth, the second-richest man in
the world has joined the hunt.
In hopes of stopping the process of aging, Larry Ellison, the
brassy 55-year-old chief executive of Oracle, is quietly pumping
millions of dollars into research and other investments. He's now
the single largest private supporter of research in aging, and he's
opening the spigot further.
Ellison's efforts come at a time when interest in age-related
research is booming, spurred by breakthroughs in science that could
soon promise billions and perhaps trillions of dollars in profits.
Behind that interest are the aging baby boomers, the large number
of people born in the prosperity that came after World War II, who
have hit or are nearing their golden years. Few embody the
preoccupation with age more than Ellison.
``Most people accept early on that they will die,'' said Ellison
biographer Mark Wilson. ``But part of Larry Ellison is saying if
he's smart enough, he should be able to beat it. . . . Death is
just another kind of corporate opponent that he can outfox.''
Ellison and Oracle declined to comment last week. But in a previous
speech, Ellison said the cost of health care for an aging
population ``will literally bankrupt the nation,'' and that the
boomers, including himself, are a ``demographic sword of Damocles''
hanging over the necks of younger generations.
Scientists generally agree that human life can be extended, but are
divided about how much. Optimists hope a breakthrough in the next
30 years will extend human life to 150 years or more, but
conservatives believe life will be extended slowly, as a side
effect of regenerative drugs.
The investment community is taking note.
Steve Jurvetson, a partner at the venture-capital firm Draper
Fisher Jurvetson, is scouting out ways to get into the field. He
believes that within 30 years, people will live 120 to 140 years.
His partner, Tim Draper, has invested privately in a Sunnyvale
firm, Layton Bioscience, which is refining a process of cell
regeneration to cure brain damage after a stroke. Layton CEO Gary
Snable said the work is directly applicable to extending age. This
week, Layton is expected to close a $30 million round of funding.
Generating big money
Big-name venture firm Kleiner Perkins Caufield & Byers has invested
in publicly traded Geron. And Peter Friedli has invested in Osiris
Therapeutics, which works with adult stem cells.
This month, Friedli joined Oracle to invest in Myriad Genetics,
which researches the human proteome. It is Oracle's first foray
into biotech.
However, researchers say Ellison's money is the most crucial
because itseeds research at the earliest stages.
``Ellison's money has been extremely important,'' said Thomas
Johnson, a University of Colorado geneticist who is trying to
extend the lifespan of mice.
Ellison has shown a lifelong fascination with science and age.
Born to an unwed mother in 1944, Ellison was adopted by relatives
and raised in a middle-class Jewish home in Chicago. A friend's
father, a chemical researcher, became a role model. Ellison applied
for medical school but never went.
Ellison later met Nobel laureate Joshua Lederberg. They schmoozed
most of the night at Ellison's villa in Atherton, talking mostly
about biotech, Lederberg said. Lederberg then invited Ellison to
his lab for a two-week ``vacation'' handling DNA in strains of
bacteria -- ``so he could get his hands dirty,'' Lederberg said.
Ellison's adoptive mother died of cancer when he was in college. He
said later that he didn't tell anyone about it for years.
Later, Robert Miner, co-founder of Oracle, also died of cancer at
52. Ellison pretended Miner didn't have cancer or wouldn't have it
for long, according to those close to him.
``He was getting to an age when he was feeling vulnerable,'' said
Lederberg. Ellison insisted on keeping Miner on the payroll,
according to Wilson's 1997 biography, ``The Difference Between God
and Larry Ellison.''
``Dad and Larry were both into living forever, the Fountain of
Youth kind of stuff,'' said Nicola Miner, his daughter, in the
Wilson biography. ``I think that my dad's illness really freaked
him out. My dad always said that Larry had a hard time facing his
own mortality.''
When Ellison was told of Miner's death, he reportedly demanded
proof.``It doesn't make any sense to me,'' Ellison later told
Wilson. ``Death has never made any sense to me. How can a person be
there and then just vanish, just not be there? Clearly the reason
they're not there is they're off doing something else. Like Bob
was. . . . Death makes me very angry. Premature death makes me
angrier still.''
Obsession with youth
Every aspect of Ellison's life is youth-oriented, Wilson said, from
physical fitness and a penchant for carrot juice to a love of cars
and women and a nose job at an early age.
Some say his obsession with youth has spilled into the workplace.
Ellison is being sued for age discrimination by Randy Baker, a
former Oracle executive. Baker, who is 55 -- the same age as
Ellison -- contends Ellison made several derogatory comments about
age and older workers.
Baker was demoted, replaced by a manager who is about 40, and then
fired. Ellison's attorneys would not comment on the pending case.
Ellison's investments into age research have slowly grown. He
funded research at the University of California on DHEA, a hormone
some believe could retard aging. Through his private venture fund,
Tako Ventures, he has made investments in several other biotech
companies.
Centenarians studied
One was Aeiveos -- named after Greek words for ``forever'' and
``young'' -- founded by Robert Bradbury, an early employee at
Oracle. Aeiveos studied the genetic codes of centenarians, those
who live to the ripe old age of 100 and more.
But soon it became clear that without a basic scientific
breakthrough, profits were elusive, observers said. Ellison
installed his former employee to run the company despite little
knowledge of the field, some said. Bradbury, a Harvard dropout, is
an Extropian, a group of believers in the idea that genetic
engineering will prolong life.
``I find it intriguing,'' said Johnson, the scientist, ``that Larry
Ellison was bankrolling them, but unlike his astuteness in running
computer engineering, he ignored people who knew what was going on
in the field he was funding.''
Ellison has committed $20 million a year to aging research through
a newly created Ellison Medical Foundation. As of January, the
foundation is investing $45 million a year, $25 million of which is
to fight global infectious disease.
Ellison put Lederberg on the board, and recruited another big
player: Richard Sprott, former director of the Biology of Aging
program at the National Institute of Aging.
Sprott said Ellison is ``hands-on'' in funding decisions. But some
say Lederberg and Sprott have reined him in.
`I think Ellison is more interested in the radical stuff,'' says
Max More, president of the Extropy Institute, who has kept close
tabs on funding in the field.
The foundation funds scores of academics studying aging, to get
them to the stage where government or venture-capital funding can
take over.
Several of the researchers Ellison has funded are now seeking to
turn profits. One is Cynthia Kenyon, who extended the lifespan of
worms 300 percent. She has teamed up with an associate of Arch
Venture Capital, Cindy Bayley, to form a company called Elixir.
Meanwhile, profits or no profits, the world -- and Ellison -- will
have to be patient.
``Even if the Fountain of Youth is discovered,'' Lederberg said,
``it will be 10 years before anyone got any benefit.''
This archive was generated by hypermail 2.1.5 : Sat Nov 02 2002 - 08:07:24 MST